Search Results
Your search for ,USE matches 11188 pages
Showing 1001 - 1050Patients With Early-Stage HR-Positive Breast Cancer May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
Newly published study results revealed that use of the Breast Cancer Index (BCI) test led to physicians changing their long-term antiestrogen treatment recommendations for 40% of patients with early-stage hormone receptor–positive breast cancer. The results, which suggest that many women may be...
Physician Attitudes Toward 2020 ACS Cervical Cancer Screening Guidelines
Investigators have uncovered that despite low adoption rates of the 2020 American Cancer Society (ACS) cervical cancer screening guidelines among physicians, a majority of them expressed willingness to utilize the recommendations under certain circumstances, according to a recent study published by ...
Variations in Use of Chemotherapy in Patients With Newly Diagnosed Common Cancers
In an International Cancer Benchmarking Partnership study reported in The Lancet Oncology, McPhail et al found wide interjurisdictional variation in chemotherapy use among patients with newly diagnosed common cancers in Norway, the United Kingdom, Canada, and Australia. Study Details The study...
NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and Other Cancers
The National Comprehensive Cancer Network® (NCCN®) is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The evidence-based expert consensus recommendations are the most frequently updated guidelines for...
Can HPV ctDNA Guide the Adjuvant Treatment of Oropharyngeal Cancer?
Although liquid biopsies are now helping determine the need for adjuvant therapy in a number of malignancies, they have yet to prove useful in the setting of oropharyngeal carcinoma, according to a prospective pilot study presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium that...
Impact of Behavioral Health Disorders on Cancer Surgery Outcomes
Investigators may have uncovered new insights into the relationship between behavioral health disorders and cancer surgery outcomes, according to a recent study published by Katayama et al in the Journal of the American College of Surgeons. The findings clarified the need for behavioral health...
AUA, ASTRO, SUO Release Clinical Practice Guidelines on Salvage Therapy for Prostate Cancer
The American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released new clinical practice guidelines on salvage therapy for patients with prostate cancer. These guidelines were reported on by Morgan...
Online Genetic Education Programs May Spur Testing for Patients at Risk for Cancer
Researchers have demonstrated that an online genetic education program may encourage patients with a family history of cancer to undertake genetic testing, according to a recent study published by Rodriguez et al in Gastroenterology. Background Although research has shown that an inherited...
Exposure to Secondhand Smoke During Chemotherapy May Decrease Treatment Efficacy in Patients With Head and Neck Cancer
Researchers have found that exposure to secondhand smoke during treatment with cisplatin may reduce its effectiveness in patients with head and neck cancer, even if they don’t have a history of smoking, according to a recent study published by Sadhasivam et al in the International Journal of...
Romidepsin Plus CHOP in Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of Ro-CHOP Trial
As reported in the Journal of Clinical Oncology by Camus et al, the final analysis of the phase III Ro-CHOP trial showed no significant progression-free or overall survival benefit with the addition of romidepsin (Ro) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously...
Adding First-Line Nivolumab to Chemotherapy in Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
As reported in the Journal of Clinical Oncology by Yelena Y. Janjigian, MD, and colleagues, 3-year follow-up of the phase III CheckMate 649 trial has shown the continued benefit of the addition of nivolumab to chemotherapy in the first-line treatment of advanced gastric, gastroesophageal junction,...
Celebrating Advances in Cancer Care and a Look at How AI Is Revolutionizing Oncology
For the third year in a row, more than 250 leaders in cancer care, including cancer center directors, physicians, scientists, ethicists, journalists, public officials, and patient advocates, gathered at the Richard Nixon Presidential Library and Museum in Yorba Linda, California, to attend the...
Highlights From the 2023 San Antonio Breast Cancer Symposium
Studies presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) significantly moved the needle forward in our treatment of breast cancer. We are increasingly learning how to stratify risk, so we can optimize therapy and minimize our patients’ exposure to treatments that will not be...
IDEA Trial: Might Radiation One Day Be Safely Omitted for Younger, Favorable-Risk, Postmenopausal Patients With Breast Cancer?
Investigators used low recurrence scores on a genomic assay as guidance for selection of favorable-risk patients, and they found most postmenopausal patients (aged 50–69) with stage I hormone receptor–positive breast cancer who omitted adjuvant radiation therapy but continued endocrine therapy for...
Long-Term Follow-up Supports Postneoadjuvant T-DM1 Over Trastuzumab in Early, High-Risk, HER2-Positive Breast Cancer
At a median follow-up of 8.4 years, adjuvant use of ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. These ...
Novel PI3K Inhibitor as Part of Triplet Improves Outcomes in Hormone Receptor–Positive, HER2-Negative Breast Cancer
The addition of inavolisib to first-line treatment with palbociclib plus fulvestrant more than doubled progression-free survival in patients with recurrent PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer, according to a late-breaking primary analysis of the phase III ...
HER2CLIMB-02: Tucatinib Plus T-DM1 Extends Progression-Free Survival vs T-DM1 Alone in Advanced HER2-Positive Breast Cancer
Adding the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) to the HER2-targeted agent tucatinib extended progression-free survival by about 2 months vs treatment with T-DM1 alone among patients with unresectable, locally advanced or metastatic HER2-positive breast cancer, according to...
Families of Men With Subfertility May Have Increased Risk of Several Types of Cancers
Investigators have found that the families of subfertile men may have a higher risk of developing certain types of cancers at younger ages compared with the families of fertile men, according to a recent study published by Ramsay et al in Human Reproduction. Background Previous research has shown...
Exploring the Role of Intravenous Mistletoe Extract in Treating Metastatic Solid Tumors
Guest Editor’s Note: The use of mistletoe extract to support systemic therapy and improve quality of life for patients with cancer, though common, remains controversial. Promising results have been reported, but largely in trials that were not placebo-controlled nor properly randomized. In this...
IDEA Trial: Might Radiation One Day Be Safely Omitted for Younger, Favorable-Risk, Postmenopausal Patients With Breast Cancer?
Investigators used low recurrence scores on a genomic assay as guidance for selection of favorable-risk patients, and they found most postmenopausal patients (aged 50–69) with stage I hormone receptor–positive breast cancer who omitted adjuvant radiation therapy but continued endocrine therapy for...
Evaluating the Use of Perioperative Chemoimmunotherapy in Resectable Gastric and Gastroesophageal Junction Cancers
Updates of two key phase III trials presented at the 2024 ASCO Gastrointestinal Cancers Symposium showed the benefit of adding a checkpoint inhibitor to standard perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) in locally advanced, resectable gastric and...
Understanding Risk Stratification in Monoclonal Gammopathy of Undetermined Significance
About 4 years ago, I [Jo Cavallo] wrote about the death of my brother Dom from multiple myeloma in 2011 and my subsequent enrollment in the PROMISE trial (ClinicalTrials.gov identifier NCT03689595). My goal for enrolling in the study was twofold: to honor Dom and others with the cancer and to make ...
First-Line Radioligand-Based Therapy Demonstrates Benefit in Some Neuroendocrine Tumors
Adding the radioligand lutetium-177 dotatate (Lu-177 dotatate) to standard therapy almost tripled the median progression-free survival in patients with untreated, high-grade, gastroenteropancreatic neuroendocrine tumors in the randomized phase III NETTER-2 study, researchers reported at the 2024...
High-Risk Non–Muscle-Invasive Bladder Cancer: Reduced Induction Courses of BCG
As reported by Katims et al in JAMA Oncology, long-term follow-up of a single-center phase II study showed benefit with two induction courses of bacillus Calmette-Guérin (BCG) without maintenance in patients with high-risk non–muscle-invasive bladder cancer. The strategy markedly reduced the number ...
NIH’s New Cancer Screening Research Network Could Help Determine Effective Cancer Screening Technologies
The National Institutes of Health (NIH) has launched the Cancer Screening Research Network, a clinical trials network to evaluate emerging cancer screening technologies. The new network will support the Biden-Harris Administration’s Cancer Moonshot initiative by investigating how to identify cancer ...
Prophylactic Oral Vancomycin May Prevent C Difficile Infections, Raise Risk of Gram-Negative Bacteremia in Stem Cell Transplant Recipients
Preventive use of the oral antibiotic vancomycin may be effective at reducing the risk of Clostridioides difficile infections but may increase the risk of gram-negative bacteremia in stem cell transplant recipients, according to new findings presented by Vartanov et al at the 2024 Tandem Meetings:...
Rapid Guideline Update on Radiotracers for Determining Radioligand Treatment Eligibility in Metastatic Castration-Resistant Prostate Cancer
ASCO has released a guideline rapid recommendation update addressing radiotracers used for prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) diagnostic imaging for selecting patients with metastatic castration-resistant prostate cancer (mCRPC) to receive...
All-Oral Regimen Feasible and Effective in Acute Promyelocytic Leukemia, Study Finds
An all-oral regimen for newly diagnosed acute promyelocytic leukemia (APL) was shown to be “highly effective and safe,” eliminating the need for chemotherapy altogether in many patients, Hong Kong researchers reported at the 2023 American Society of Hematology (ASH) Annual Meeting &...
Postdiagnosis Mental Disorders Among AYAs With Cancer
In a Canadian study reported in the Journal of Clinical Oncology, Oberoi et al found that adolescents and young adults (AYAs) with cancer were at an increased risk of mental disorders compared with cancer-free matched population-based and sibling cohorts. Study Details The retrospective...
Perioperative Tislelizumab Plus Chemotherapy in Resectable NSCLC
In patients with resectable non–small cell lung cancer (NSCLC), perioperative treatment with the checkpoint inhibitor tislelizumab plus platinum-doublet chemotherapy led to a statistically significant benefit in event-free survival and a favorable trend for overall survival, investigators for the...
Final Results of the POUT Trial: Adjuvant Chemotherapy vs Surveillance After Nephroureterectomy for Upper Tract Urothelial Cancer
As reported in the Journal of Clinical Oncology by Alison Jane Birtle, MD, MBBS, MRCP, FRCR, and colleagues, final results of the UK-based phase III POUT trial showed survival benefits with adjuvant platinum-based chemotherapy vs surveillance after radical nephroureterectomy in patients with upper...
Expert Point of View: Dipenkumar Modi, MD
The ASCO Post obtained comments on the Smart Stop study from Dipenkumar Modi, MD, a medical oncologist and hematologist at the Barbara Ann Karmanos Cancer Institute and Assistant Professor of Oncology at Wayne State University School of Medicine, Detroit. Dr. Modi applauded the investigators for...
Expert Point of View: Carla Casulo, MD
Session co-moderator Carla Casulo, MD, offered her thoughts on the response-adapted use of ultra-low–dose radiotherapy in gastric MALT (mucosa-associated lymphoid tissue) lymphoma, as reported by the investigators from MD Anderson Cancer Center. Dr. Casulo is Associate Professor of Medicine and...
Expert Point of View: Cynthia E. Dunbar, MD
In a press briefing at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, Cynthia E. Dunbar, MD, ASH Secretary and Chief of the Translational Stem Cell Biology Branch, Intramural Research Program of the National Heart, Lung, and Blood Institute, offered her thoughts on...
Expert Point of View: Ajay K. Nooka, MD, MPH, and Dan Vogl, MD, MSCE
Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology at Emory University, and Dan Vogl, MD, MSCE, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, shared their thoughts on the PERSEUS trial for The ASCO Post. Dr. Nooka noted that ...
Expert Point of View: Michael Crump, MD
Michael Crump, MD, of the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, expressed some concerns about the study presented by Shadman et al in patients with large B-cell lymphoma (LBCL). “These data should be interpreted with caution. The patient...
Should You Reconsider Transplant for Relapsed Large B-Cell Lymphoma in Complete Remission?
For patients with relapsed large B-cell lymphoma (LBCL) in complete remission, outcomes were better after autologous stem cell transplantation (ASCT) than with chimeric antigen receptor (CAR) T-cell therapy in a retrospective analysis of a large database presented at the 2023 American Society of...
Expert Point of View: Peter Voorhees, MD
Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Durham, North Carolina, introduced the plenary presentation of the phase III IsKia trial by Gay et al and further commented on the study for The ASCO...
Canadian Study Shows Myeloma Outcomes in the Real World May Be Worse Than Clinical Trials Suggest
Patients with multiple myeloma treated in the “real world” had worse outcomes than patients who received the same treatment on clinical trials, according to research presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In a pooled analysis of clinical trial...
PERSEUS: Daratumumab Regimen Significantly Improves Progression-Free Survival in Newly Diagnosed Multiple Myeloma
The addition of the CD38 monoclonal antibody daratumumab to a standard regimen for patients with newly diagnosed transplant-eligible multiple myeloma significantly prolonged progression-free survival vs standard treatment in the phase III PERSEUS trial. The study was reported as a late-breaking...
Triplet for Advanced HER2-Negative Breast Cancer
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research published by Roussos Torres et al in Nature Cancer. The regimen included a histone deacetylase (HDAC) inhibitor combined with two types of checkpoint...
Understanding the Discordance About Prognosis Between Clinicians and Terminally Ill Patients and Their Surrogates
Research shows that about half of adults near the end of life in the United States are too ill to participate in decisions about whether to accept life-prolonging treatment,1 requiring family members and other proxies to serve as surrogate decision-makers for their critically ill loved ones....
Neoadjuvant Immunotherapy May Improve Long-Term Survival in Patients With Resectable Soft-Tissue Sarcoma
Patients with soft-tissue sarcoma treated with neoadjuvant immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to phase II trial results published by Roland et al in Nature Cancer. Background About 13,000 new cases of soft-tissue...
All-Oral Regimen Feasible and Effective in Acute Promyelocytic Leukemia, Study Finds
An all-oral regimen for newly diagnosed acute promyelocytic leukemia (APL) was shown to be “highly effective and safe,” eliminating the need for chemotherapy altogether in many patients, Hong Kong researchers reported at the 2023 American Society of Hematology (ASH) Annual Meeting &...
Shedding Light on Mechanisms Behind Fulvestrant Resistance in Advanced ER-Positive Breast Cancer
Researchers may have uncovered the factors contributing to hormone therapy resistance in some patients with advanced estrogen receptor (ER)-positive breast cancer, according to a recent study published by Kingston et al in Cancer Discovery. The findings may indicate drugs currently in development...
High-Risk Localized Prostate Cancer: Survival Benefit With Long-Term ADT and Dose-Escalated Radiation Therapy
Men with high-risk localized prostate cancer had a significant survival benefit when treated with a more intensified regimen of dose-escalated radiation therapy plus long-term androgen-deprivation therapy (ADT) vs standard radiation therapy plus ADT, according to long-term follow-up from the...
Machine-Learning Model May Predict Oxaliplatin Benefit in Colon Cancer
The novel COLOXIS machine learning model may accurately predict which patients with colon cancer are most likely to derive benefit from oxaliplatin, according to a recent study published by Chen et al in the Journal of Clinical Oncology. The findings could ultimately allow physicians to better...
High Reoperation Rates Following Breast-Conserving Surgery May Increase Cost of Care and Risk of Complications
Investigators have uncovered high rates of reoperation following initial breast-conserving surgery in patients with breast cancer that may contribute to increased costs of cancer care and a higher risk of postoperative complications, according to a recent study published by Kim et al in the Annals...
Reflections on Cancer’s Toll on My Family
Over the past 2 years, my family and I have experienced firsthand the challenges of cancer. In the spring of 2021, my mother was diagnosed with stage IIB pancreatic cancer. She died in mid-2023 after developing metastatic disease, including peritoneal carcinomatosis. The experience has caused me to ...
Metastatic Castration-Resistant Prostate Cancer: LuPSMA vs Cabazitaxel
As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, the Australian phase II TheraP trial has shown similar overall survival with lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) vs cabazitaxel in patients with prostate-specific membrane...
